Mirum Pharmaceuticals (MEX:MIRM) Retained Earnings: MXN-26,286 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:MIRM Mirum Pharmaceuticals Inc MEX:MIRM
50 GF Score
Price MXN1,256.12
GF Value MXN893.03
! 6 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals Retained Earnings?

Mirum Pharmaceuticals MEX:MIRM 50 Retained Earnings is MXN-26,286 Mil as of Mar. 2026. GuruFocus rates MEX:MIRM with a GF Score™ of 50/100 and a GF Value™ of MXN893.03. The stock has 6 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Mirum Pharmaceuticals's retained earnings for the quarter that ended in Mar. 2026 was MXN-26,286 Mil.

Mirum Pharmaceuticals's quarterly retained earnings increased from Sep. 2025 (MXN-12,140 Mil) to Dec. 2025 (MXN-12,020 Mil) but then declined from Dec. 2025 (MXN-12,020 Mil) to Mar. 2026 (MXN-26,286 Mil).

Mirum Pharmaceuticals's annual retained earnings declined from Dec. 2023 (MXN-9,442 Mil) to Dec. 2024 (MXN-13,435 Mil) but then increased from Dec. 2024 (MXN-13,435 Mil) to Dec. 2025 (MXN-12,020 Mil).


Mirum Pharmaceuticals  (MEX:MIRM) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Mirum Pharmaceuticals Retained Earnings Historical Data

* Premium members only.

The historical data trend for Mirum Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mirum Pharmaceuticals Retained Earnings Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial -5,275.36 -7,658.50 -9,441.74 -13,434.85 -12,019.60

Mirum Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13,479.05 -12,516.13 -12,140.45 -12,019.60 -26,286.25
MEX:MIRM
50GF Score
Mirum Pharmaceuticals Inc MEX:MIRM
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mirum Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of MXN-26,286 Mil mean?
Mirum Pharmaceuticals (MEX:MIRM) has a Retained Earnings of MXN-26,286 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Mirum Pharmaceuticals and its competitors.
Is Mirum Pharmaceuticals' Retained Earnings too high?
Mirum Pharmaceuticals' current Retained Earnings is MXN-26,286 Mil. Overall, Mirum Pharmaceuticals has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Retained Earnings compare to RYTM and SYRE?
Mirum Pharmaceuticals' Retained Earnings of MXN-26,286 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current Retained Earnings is MXN-26,286 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Mirum Pharmaceuticals (MEX:MIRM) has a current Retained Earnings of MXN-26,286 Mil. The stock's GF Value™ is MXN893.03, compared to a current price of MXN1,256.12 — trading 40.7% above its estimated fair value. The current Retained Earnings is MXN-26,286 Mil. Mirum Pharmaceuticals' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Mirum Pharmaceuticals (MEX:MIRM), the current Retained Earnings is MXN-26,286 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mirum Pharmaceuticals (MEX:MIRM) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,256.12 is trading 40.7% above its estimated GF Value™ of MXN893.03.

Key valuation signals for MEX:MIRM:

  • Retained Earnings: MXN-26,286 Mil
  • GF Value™: MXN893.03 vs. price of MXN1,256.12 (40.7% above fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the MEX:MIRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mirum Pharmaceuticals Business Description

Other Exchanges MIRM:USA08D:Germany
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
50GF Score

Get the complete analysis for MEX:MIRM

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,256.12
Price
MXN893.03
GF Value